BRADO
Brimonidine tartrate 0.2%
BRADO is an antiglaucoma eye drops contains brimonidine tartrate 0.2%
Which is the only selective a2-adrenergic receptor agonist approved for
chronic treatment in glaucoma / Therapeutic Indications Reduction of As monotherapy In patients with open-argh glaucoma or When therapy
BRADO
Brimonidine tartrate 0.2%
BRADO is an antiglaucoma eye drops contains brimonidine tartrate 0.2%
Which is the only selective a2-adrenergic receptor agonist approved for
chronic treatment in glaucoma / Therapeutic Indications Reduction of As monotherapy In patients with open-argh glaucoma or When therapy
Amman Pharmaceutical Industries (API) was established in 1989 as one of the first pharmaceutical companies in the MENA region to pioneer the production of niche branded generics in the therapeutic areas of Ophthalmology, ENT (Ear, Nose & Throat ) , respiratory, and Dermatology. After many years of success.
